Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of 3D thoracic radiotherapy with or without erlotinib in unresectable localized or locally advanced non-small cell lung cancer not suitable for chemotherapy
2005-004124-39Phase 2Active
- Sponsor
- Dr. Enrique Martínez López
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dr. Enrique Martínez López. Primary endpoints: Grade 3-4 toxicity during treatment and Feasibility of erlotinib plus 3D thoracic radiotherapy. Started Nov 2005; status: active.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004124-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004124-39.